Abstract:Background Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in destruction of joint cartilage and bone. However, many patients do not achieve satisfactory disease control by current therapy with high risk of adverse reactions. We have reported that absolute number of peripheral regulatory T (Treg) cells reduced in RA patients (EULAR Abstract). Moreover, rapamycin has been reported to inhibit differentiation of Th17 and promote growth of FoxP3 +Treg cells by inhibiting mTOR pathway [1]. Objectives To observe the therapeutic efficacy of rapamycin on the reduction of disease activity, increase in Tregs and decrease in Th17 to restore balance of Th17/Treg cells in RA patients with high disease activity (DAS28 ≥2.6). Methods Fifty RA patients who treated with two kinds of DMARDs for more than half a year did not achieve remission (DAS28 ≥2.6) were enrolled and were treated with rapamycin at a dose of 0.5 mg every 2 days for 24 weeks. The absolute number of CD4 +T cell subsets in peripheral blood from these patients were assessed by flow cytometry combined with internal standard beads before the treatment as baseline and at week 24 after treatment. Meantime, the DAS28, the dosage of corticosteroids and immunosuppressant were also recorded. Results Rapamycin treatment reduced the disease activity and induced remission (DAS28<2.6) in 44.9% of active RA patients. Their DAS28 was reduced from a median 2.9 (at week 0) to 1.9 (at week 24) (P<0.001) and the absolute number of peripheral Treg cells was increased from 27.14±15.11 cells/µl (at week 0) to 36.59±17.23 cells/µl (at week 24) (p=0.002). The ratios of Th17/Treg cells also had a significant decrease from 0.36±0.29 at baseline to 0.27±0.20 at week 24 (P<0.041). In contrast, the decrease in the absolute number of Th17 cells was not statistically significant (p=0.846). After the treatment, the proportion of patients taking glucocorticoids decreased from 66.0% to 64.0% and the mean dosage of prednisone decreased from 9.89 mg/d to 7.70 mg/d. And the usages of DMARDs were also reduced (P<0.001). Conclusions Rapamycin combined with low level of conventional therapy effectively reduced disease activity and induced remission among RA patients who received long-term conventional treatment without remission (DAS28 ≥2.6) by increasing the absolute number of Treg cells and restoring the balance of Th17 cells and Treg cells. As the research progresses, rapamycin is likely to become a promising therapeutic candidate. Reference [1] Shan J, Feng L, Sun G, et al. Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells. Immunobiology2015;220(4):510–517. Disclosure of Interest None declared

Use of Rituximab in Rheumatoid Arthritis

Clinical Application of Rituximab in Rheumatoid Arthritis

Usefulness of Tocilizumab for Treating Rheumatoid Arthritis with Myelodysplastic Syndrome

B cell depletion in autoimmune rheumatic diseases

Efficacy and Safety of Rituximab Therapy for Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis

Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases

Rituximab in B-cell disorders other than non-Hodgkin's lymphoma

[Rituximab and autoimmune disorders therapy]

Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.

AB0376 Rapamycin induces remission in patients with newly diagnosed rheumatoid arthritis

Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

FRI0063 Rapamycin Induces Remission in Patients with Refractory Rheumatoid Arthritis

Efficacy of individualized rituximab as the rescue therapy for active lupus nephritis with acute kidney injury

Rituximab therapy for adult patients with idiopathic focal segmental glomerulosclerosis

Rituximab in autoimmune hematologic diseases: not just a matter of B cells

Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies

The emerging role of Rituximab in the treatment of large granular lymphocytic leukemia associated with rheumatoid arthritis: a single center experience

Mechanism of action of rituximab

Rituximab in systemic lupus erythematosus and lupus nephritis

The potential utility of B cell-directed biologic therapy in autoimmune diseases